CoCliP-BJI study: cost avoidance of clinical pharmacist-led interventions in patients with bone and joint infections

IF 2.9 4区医学 Q2 INFECTIOUS DISEASES

Infectious diseases now Pub Date : 2025-05-28 DOI:10.1016/j.idnow.2025.105104

Eloïse Couvé , Marin Lahouati , Julie Leitao , Vasco Dias Meireles , Fréderic-Antoine Dauchy , Fabien Xuereb

{"title":"CoCliP-BJI study: cost avoidance of clinical pharmacist-led interventions in patients with bone and joint infections","authors":"Eloïse Couvé , Marin Lahouati , Julie Leitao , Vasco Dias Meireles , Fréderic-Antoine Dauchy , Fabien Xuereb","doi":"10.1016/j.idnow.2025.105104","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Patients with bone and joint infections (BJI) are part of a complex care pathway. This study aimed to evaluate the economic impact of clinical pharmacist-led interventions in the management of BJI patients.</div></div><div><h3>Patients and Methods</h3><div>We performed a retrospective study documenting all pharmacist-led interventions (PI). Their impact was assessed using the clinical economic and organizational scale (CLEO SFPC). The probability of adverse drug events (ADE) in the absence of PI was assessed by a panel of three experts. Cost avoidance was calculated for PIs with major clinical impact using a cost of €5,331 per event, multiplied by the probability of ADE occurrence.</div></div><div><h3>Results</h3><div>A total of 41 PIs had a major clinical impact. Cost avoidance associated with the intervention of a pharmacist was estimated at €83,750.01 during the study.</div></div><div><h3>Conclusion</h3><div>The implementation of pharmacist-led interventions in the management of patients with BJI helps avoid preventable healthcare costs.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 6","pages":"Article 105104"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991925000831","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Patients with bone and joint infections (BJI) are part of a complex care pathway. This study aimed to evaluate the economic impact of clinical pharmacist-led interventions in the management of BJI patients.

Patients and Methods

We performed a retrospective study documenting all pharmacist-led interventions (PI). Their impact was assessed using the clinical economic and organizational scale (CLEO SFPC). The probability of adverse drug events (ADE) in the absence of PI was assessed by a panel of three experts. Cost avoidance was calculated for PIs with major clinical impact using a cost of €5,331 per event, multiplied by the probability of ADE occurrence.

Results

A total of 41 PIs had a major clinical impact. Cost avoidance associated with the intervention of a pharmacist was estimated at €83,750.01 during the study.

Conclusion

The implementation of pharmacist-led interventions in the management of patients with BJI helps avoid preventable healthcare costs.

查看原文本刊更多论文

CoCliP-BJI研究：临床药师主导的骨和关节感染患者干预措施的成本规避

目的：骨和关节感染（BJI）患者是复杂护理途径的一部分。本研究旨在评估临床药师主导的干预BJI患者管理的经济影响。患者和方法：我们进行了一项回顾性研究，记录了所有药剂师主导的干预措施（PI）。使用临床经济和组织规模（CLEO SFPC）评估其影响。在没有PI的情况下，由三名专家组成的小组评估药物不良事件（ADE）的概率。使用每个事件5331欧元的成本乘以ADE发生的概率，计算具有重大临床影响的pi的成本避免。结果：41例PIs有重要的临床影响。在研究期间，与药剂师干预相关的成本避免估计为83,750.01欧元。结论：在BJI患者管理中实施药师主导的干预措施有助于避免可预防的医疗费用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊